ArticleJournal of inflammation research2026
Lactate Dehydrogenase as a Potential Mediator Between Immature Granulocytes and Tumor Burden in Breast Cancer.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammation and metabolic dysregulation contribute to breast cancer initiation and progression. Immature granulocytes (IG) and lactate dehydrogenase (LDH) reflect systemic inflammation and metabolic activity, respectively, but their interplay in tumor growth remains unclear. Objective: To investigate the associations among IG, LDH, and breast tumor size, and to evaluate whether LDH mediates the relationship between IG and tumor burden. Methods: A total of 778 breast cancer patients undergoing primary surgery were included. Peripheral blood IG counts and LDH levels were measured within two weeks preoperatively, and tumor size was obtained from postoperative pathology reports. Associations were assessed using SHAP feature importance analysis, univariate and multivariate linear regression, weighted linear regression, and subgroup analyses. Mediation analysis evaluated the potential mediating role of LDH. Results: In weighted and multivariable linear regression analyses, both IG count and LDH levels were significantly positively associated with tumor size. After full adjustment, IG remained an independent predictor of tumor size (β = 6.09, P = 0.01), and LDH showed a similar association (β = 0.01, P = 0.014). IG count was also strongly correlated with LDH levels (β = 241.52, 95% CI: 86.97-396.06, P < 0.01). Mediation analysis indicated that LDH partially mediated the IG-tumor size association, accounting for 9.86% of the total effect. Subgroup analysis suggested that the relationship between IG and tumor size is modulated by hypertension. Conclusion: These findings suggest a potential interplay between systemic inflammation and tumor metabolism in breast cancer progression. IG and LDH may serve as accessible biomarkers associated with tumor burden and could assist in risk stratification and clinical decision-making. Multicenter prospective studies are required to validate these associations and further elucidate the underlying biological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.